Calidi Biotherapeutics Publishes Presentation on CLD-401 Tumor Regression in Mouse Models

PUBT · 1d ago
Calidi Biotherapeutics Publishes Presentation on CLD-401 Tumor Regression in Mouse Models
  • Calidi Biotherapeutics published a medical research presentation reporting preclinical results for CLD-401, its IL-15 superagonist gene therapy.
  • Single-dose CLD-401 induced tumor regression and complete responses in mouse breast and bladder cancer models.
  • Bladder cancer models showed therapeutic activity with both intravenous and intratumoral administration.
  • Tumor-targeted IL-15 superagonist production showed minimal systemic exposure, with no detectable payload production in five tested human primary cell types.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Calidi Biotherapeutics Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.